Award recordCONTRACT

GOLDEN STATE MEDICAL SUPPLY, INC.

PIID 36E79726D0015· VA Staff Offices· NAC PHARMACEUTICALS (36E797)· 6505 · DRUGS AND BIOLOGICALS· FY2026· $0 net obligations· UEI GQLDJJ8AQNN5· CA

Description

CHANGE VENDOR POC FROM TRUDY NICKELSON TO BRIAN CURRENT 805-477-9866 X240 BCURRENT@GSMS.US

Base award description: NEW AWARD FOR VENLAFAXINE HCL TABLETS WITH MARLEX PHARMACEUTICALS, INC. PERIOD OF PERFORMANCE IS 2/28/2026 - 2/27/2027 WITH 4 ONE-YEAR OPTION PERIODS.

First action · last action
2026-01-16 · 2026-04-27
Transactions
2
First transaction's obligation
$0
Base + all options value (sum of deltas)
$4,064,496
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$1$0Base award · 2026-01-16 · this action $0 · running total $0Modification P00001 · 2026-04-27 · this action $0 · running total $0
  • Base2026-01-16+$0= $0
  • Mod P000012026-04-27+$0= $0
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2026-01-16+$0$0NEW AWARD FOR VENLAFAXINE HCL TABLETS WITH MARLEX PHARMACEUTICALS, INC. PERIOD OF PERFORMANCE IS 2/28/2026 - 2…
Mod P00001· OTHER ADMINISTRATIVE ACTION2026-04-27+$0$0CHANGE VENDOR POC FROM TRUDY NICKELSON TO BRIAN CURRENT 805-477-9866 X240 BCURRENT@GSMS.US

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI GQLDJJ8AQNN5)

AwardOffice · PSC / listingNet obligationsFY
36E79726D0041NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79726D0042NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79726D0022NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79726D0014NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79726D0023NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79726D0018NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026

Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)

AwardRecipientOfficeNet obligationsFY
36E79726A0025CHIESI USA INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0024NEUROTECH PHARMACEUTICALS, INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0023TAKEDA PHARMACEUTICALS AMERICA, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0022AURINIA PHARMA US INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0021ALEXION PHARMACEUTICALS INCNAC PHARMACEUTICALS (36E797)$0FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79726D0015_3600 · retrieved 2026-09-26.